Center for Health Systems Innovation

Medicine & Life Sciences

1. Achilles Tendon 40%
2. Alkaline Phosphatase 11%
3. Amino Acids 12%
4. anti-Thy antibody 10%
5. Appointments and Schedules 10%
6. Area Under Curve 13%
7. Atrial Fibrillation 29%
8. Automobiles 36%
9. Breast Neoplasms 21%
10. Budesonide 14%
11. Chronic Obstructive Pulmonary Disease 29%
12. Clinical Decision-Making 10%
13. Cohort Studies 22%
14. Comorbidity 26%
15. Confidence Intervals 21%
16. Conjugated (USP) Estrogens 15%
17. Coronary Artery Disease 27%
18. Costs and Cost Analysis 10%
19. Cross-Sectional Studies 24%
20. Data Mining 50%
21. Databases 9%
22. Datasets 19%
23. Decision Trees 33%
24. Delayed Hypersensitivity 37%
25. Delivery of Health Care 48%
26. Diabetic Retinopathy 34%
27. Dialysis 9%
28. Digoxin 39%
29. Diltiazem 40%
30. Dry Eye Syndromes 40%
31. Early Detection of Cancer 31%
32. Efficiency 30%
33. Electronic Health Records 88%
34. Escherichia coli K12 46%
35. Estradiol 9%
36. Fimbriae Proteins 100%
37. Fluorescein 10%
38. Fluticasone-Salmeterol Drug Combination 17%
39. Formoterol Fumarate 15%
40. Health 39%
41. Health Literacy 10%
42. Healthcare Disparities 11%
43. Hormone Replacement Therapy 37%
44. Hospital Emergency Service 35%
45. Hospital Mortality 35%
46. Insurance Coverage 9%
47. Length of Stay 10%
48. Logistic Models 17%
49. Lyt antibodies 11%
50. Machine Learning 37%
51. Marital Status 14%
52. Medicaid 24%
53. Medicare 14%
54. MEDLINE 19%
55. Membranes 39%
56. Meta-Analysis 99%
57. Mortality 28%
58. Nephrology 39%
59. Odds Ratio 22%
60. Organizational Efficiency 18%
61. Patient Protection and Affordable Care Act 45%
62. Patient Readmission 38%
63. Patient-Centered Care 9%
64. Pediatrics 21%
65. Peptides 24%
66. Pharmaceutical Preparations 13%
67. Pharmacology 11%
68. Physicians 58%
69. Pneumocystis carinii 44%
70. Pneumocystis Infections 10%
71. Postoperative Nausea and Vomiting 42%
72. Primary Care Physicians 38%
73. Primary Health Care 74%
74. Proteins 12%
75. Psoriasis 32%
76. Quality Improvement 15%
77. Quality of Health Care 9%
78. Quality of Life 26%
79. Randomized Controlled Trials 26%
80. Research Personnel 12%
81. Rupture 28%
82. Sepsis 53%
83. Single Nucleotide Polymorphism 28%
84. Smokers 84%
85. Smoking 12%
86. Smoking Cessation 72%
87. Support Vector Machine 20%
88. Systematic Reviews 98%
89. Systemic Inflammatory Response Syndrome 45%
90. T-Lymphocyte Subsets 14%
91. Technology 10%
92. Therapeutics 15%
93. Transportation of Patients 20%
94. United States Health Resources and Services Administration 13%
95. Urban Hospitals 10%
96. Veterans 34%
97. Workflow 40%
98. Workforce 22%
99. Workload 49%
100. Wounds and Injuries 16%